Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 3, 2024
Daily News
October 3, 2024
- Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
- PeptiDream, Curium Join Hands on Radionuclide Therapy for Prostate Cancer
October 3, 2024
- New Health Minister Eager to Build Pharma Ecosystem in Japan
October 3, 2024
- AMED to Assign Staff by Seed to Ensure End-to-End Support from FY2025
October 3, 2024
- New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
- Orion to Take Over Divigel as Its 1st Product in Japan
October 3, 2024
- MHLW Plans to Ease Rules on Public Knowledge-Based Applications during Re-Examination Period
October 3, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…